FOR IMMEDIATE RELEASE

Caris Life Sciences Announces Presentation of Comprehensive Tumor Profiling Research at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Research Demonstrates Clinical Utility of Caris Molecular Intelligence and Advances Molecular Understanding of Cancer to Enable the Delivery of Precision Medicine

IRVING, Tex., May 14, 2015 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announces the acceptance of 22 clinical studies by the American Society of Clinical Oncology (ASCO) for presentation at the annual meeting to be held May 29 through June 2 in Chicago, Ill. The studies conducted in partnership with leading academic and clinical institutions provide oncologists with a better understanding of how to treat cancer based on molecular drivers identified through comprehensive tumor profiling.

Each of the studies utilize Caris Molecular Intelligence®, the company’s panomic comprehensive tumor profiling service, to facilitate biomarker comparison. Caris Molecular Intelligence’s multi-platform profiling approach includes gene sequencing (Next-Generation Sequencing [NGS] and Sanger), protein expression analysis (Immunohistochemistry [IHC]), gene copy number and translocation analysis (Chromogenic or Fluorescence in situ Hybridization [CISH or FISH]). Investigators used these methods to examine tumor samples for underlying molecular alterations that may yield insights into potentially overlapping and/or alternative therapeutic options for patients across a broad and deep range of tumor types.

“Biomarker research continues to be a critically important tool for oncologists in the clinical setting, especially for those treating rare and aggressive cancers where treatment options are limited and little evidence is available to guide care,” said Sandeep K. Reddy, M.D., Chief Medical Officer at Caris Life Sciences. “These studies highlight molecular similarities and differences between cancer subtypes and identify targetable pathways across a wide variety of malignancies. The data collectively demonstrate our ability to personalize cancer care for patients today by treating each unique cancer based on the molecular makeup of their tumors.”

Following is a schedule of notable Caris Life Sciences presentations:

- Sunday, May 31, 8:00-11:30 a.m. CT, S Hall A.
• Sunday, May 31, 8:00-11:30 a.m. CT, S Hall A.

• Monday, June 1, 8:00-11:30 a.m. CT, S Hall A.
  Poster session: Gastrointestinal (Colorectal) Cancer. “Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type microsatellite unstable (MSI-H) colorectal cancer (CRC) and association of Wnt pathway corepressor TLE-3,” presented by Namrata Vijayvergia, M.D., Fox Chase Cancer Center. Abstract #3611.

• Monday, June 1, 8:00-11:30 a.m. CT, S Hall A.

• Monday, June 1, 1:15-4:45 p.m. CT, S Hall A.

• Monday, June 1, 1:15-2:15 p.m. CT, E Hall D1.

• Monday, June 1, 1:15-4:45 p.m. CT, S Hall A.
  Poster session: Central Nervous System Tumors. “Tumor profiles of brain metastases from NSCLC, breast cancer and melanoma,” presented by David Piccioni, M.D., Ph.D., UC San Diego School of Medicine. Abstract #2060.

Following is a schedule of all additional Caris Life Sciences presentations:

• Saturday, May 30, 8:00-11:30 a.m. CT, S Hall A.

• Saturday, May 30, 8:00-11:30 a.m. CT, S Hall A.

• Saturday, May 30, 1:15-4:15 p.m. CT, S Hall A.
• Saturday, May 30, 1:15-4:15 p.m. CT, S Hall A.
  Poster session: Gynecologic Cancer. “Ovarian carcinosarcoma share similar molecular profile as ovarian serous carcinoma but not endometrial carcinosarcoma,” presented by Haider Mahdi, M.D., Cleveland Clinic. Abstract #5560.

• Saturday, May 30, 1:15-4:15 p.m. CT, S Hall A.
  Poster session: Gynecologic Cancer. “Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?” presented by Robert DeBernardo, M.D., Cleveland Clinic. Abstract #5595.

• Saturday, May 30, 1:15-4:45 p.m. CT, S Hall A.
  Poster session: Gynecologic Cancer. “Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC),” presented by Michael Friedlander, M.D., Ph.D., Prince of Wales Hospital. Abstract #5540.

• Saturday, May 30, 1:15-4:45 p.m. CT, S Hall A.

• Sunday, May 31, 8:00-11:30 a.m. CT, S Hall A.

• Sunday, May 31, 8:00-11:30 a.m. CT, S Hall A.
  Poster session: Tumor Biology. “PI3K/PTEN/Akt/mTOR pathway aberrations and co-incidence of hormone receptors and HER2 in 19,784 diverse solid tumors,” presented by Sadakatsu Ikeda, M.D., UC San Diego School of Medicine. Abstract #11042.

• Monday, June 1, 8:00-11:30 a.m. CT, S Hall A.

• Monday, June 1, 1:15-4:45 p.m. CT, S Hall A.
  Poster session: Melanoma/Skin Cancers. “Multiplatform biomarker analysis of non-sun-exposed mucosal melanoma,” presented by Alan H. Bryce, M.D., Mayo Clinic, Scottsdale, AZ. Abstract #9042.

• Monday, June 1, 8:00-11:30 a.m. CT, S Hall A.
• Monday, June 1, 1:15-4:45 p.m. CT, S Hall A.
Poster session: Melanoma/Skin Cancers. “Triple wild type melanoma profiling in the Caris Molecular Intelligence registry,” presented by Krisztian Homicsko, M.D., Ph.D., The University Hospital of Lausanne, CHUV. Abstract #9054.

• Monday, June 1, 1:15-4:45 p.m. CT, S Hall A.
Poster session: Genitourinary (Nonprostate). “Multi-platform molecular analysis of sarcomatoid renal cell carcinoma (sRCC),” presented by Thai Ho, M.D., Ph.D., Mayo Clinic, Scottsdale, AZ. Abstract #4556.

• Monday, June 1, 1:15-4:45 p.m. CT, S Hall A.

“Caris Life Sciences remains committed to advancing the molecular understanding of cancer and these studies reflect Caris’ leadership role in transforming the promise of precision medicine into a reality,” said David D. Halbert, Chairman and Chief Executive Officer at Caris Life Sciences. “We continue to strive for widespread access to comprehensive tumor profiling through research and partnerships that provide oncologists with the most amount of clinically actionable information needed to inform treatment decisions for their patients.”

About Caris Life Sciences®
Caris Life Sciences® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s healthcare information and comprehensive tumor profiling service with more than 70,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature. Since 2009, Caris has tracked clinical and outcome data for certain patients undergoing tumor molecular profiling, for which Caris has observed that patients treated with drugs consistent with their molecular profile show a significant increase in overall survival. The company is developing its Carisome® TOP™ technology, a revolutionary and proprietary blood-based platform for the development of novel therapeutics, drug delivery and drug target identification. The technology is also being developed for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout Europe, the U.S., Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

###

Media Inquiries:
David Patti
JFK Communications
dpatti@jkfhealth.com
609-456-0822